肠道菌群结构在非酒精性脂肪性肝病患者中的改变

薛平燕; 江艳; 徐玉善; 袁惠; 李璇; 宋亚贤; 刘华

doi:10.12259/j.issn.2095-610X.S20201120

肠道菌群结构在非酒精性脂肪性肝病患者中的改变

doi: 10.12259/j.issn.2095-610X.S20201120

薛平燕^{1, 2},
江艳¹,
徐玉善^1, ,,
袁惠³,
李璇⁴,
宋亚贤¹,
刘华⁵

1.
昆明医科大学第一附属医院内分泌一科，云南昆明　650032
2.
曲靖市第二人民医院内分泌科，云南曲靖　655000
3.
昆明医科大学第一附属医院超声医学科
4.
神经外二科
5.
检验科，云南昆明　650032

基金项目: 云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目[2017FE468（-044）]

详细信息

作者简介:
薛平燕（1983～），女，云南宣威人，医学硕士，主治医师，主要从事糖尿病及其并发症研究工作

通讯作者:
徐玉善，E-mail：xuyushan1019@126.com

中图分类号: R575.4
计量
- 文章访问数: 3672
- HTML全文浏览量: 2274
- PDF下载量: 18
- 被引次数: 0
出版历程
- 收稿日期: 2020-09-21
- 网络出版日期: 2020-12-03
- 刊出日期: 2020-11-25

Changes of Intestinal Flora in Non-alcoholic Fatty Liver Disease

Ping-yan XUE^{1, 2},
Yan JIANG¹,
Yu-shan XU^{1
, ,},
Hui YUAN³,
Xuan LI⁴,
Ya-xian SONG¹,
Hua LIU⁵

1.
Dept. of Endocrinology，The 1st Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032
2.
Dept. of Endocrinology，The 2nd People’s Hospital of Qujing City，Qujing Yunnan 655000
3.
Dept. of Ultrasound Medicine
4.
Dept. of Neurosurgery
5.
The Medical Laboratory Department，The 1st Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032，China

摘要

摘要: 目的测定非酒精性脂肪性肝病（nonalcoholic fatty liver disease，NAFLD）患者肠道中目标细菌的数量，探讨肠道菌群在NAFLD发生发展中的作用。方法随机选取150例NAFLD患者，60例健康对照者，采用实时荧光定量PCR法检测粪便中目标细菌DNA的表达量。结果 NAFLD患者粪便中的乳酸杆菌、直肠真杆菌数量显著增加（P = 0.00、P = 0.007），双歧杆菌、多形拟杆菌数量显著降低（P = 0.00、P = 0.022）。结论 NAFLD患者肠道中存在乳酸杆菌、直肠真杆菌、双歧杆菌、多形拟杆菌的结构失衡，肠道菌群失衡可能参与NAFLD的发生发展，改善肠道菌群失衡对NAFLD具有一定治疗价值。
- 肠道菌群 /
- NAFLD /
- 拟杆菌门 /
- 厚壁菌门
Abstract: Objective To observe the changes of intestinal flora in patients with non-alcoholic fatty liver disease （NAFLD） and the role in occurrence and development of the disease. Methods One hundred and fifty patients who were diagnosed as NAFLD and 60 healthy controls were randomly selected. Used the relative quantification of Real Time PCR to detecte the expression level of DNA of target bacteria. Results Compared to the control group, the quantity of Lactobacillus and Eubacterium rectale in NAFLD patients were significant increased, Bifidobacterium and Bacteroides thetaiotaomicron were decreased. Conclusion The quantity of Lactobacillus, Eubacterium rectale, Bifidobacterium, Bacteroides thetaiotaomicron in patients with NAFLD may exist structural imbalance of intestinal flora, gut microbiome probably participate in the occurrence and development of NAFLD, improve the intestinal flora imbalance has a certain treatment value in NAFLD.
- Intestinal flora /
- Non-alcoholic fatty liver disease /
- Phylum firmicutes /
- Bacteroidetes

HTML全文

图 1 多形拟杆菌

Figure 1. Bacteroides thetaiotaomicron

下载: 全尺寸图片幻灯片

图 2 直肠真杆菌

Figure 2. Eubacterium rectale

下载: 全尺寸图片幻灯片

图 3 双歧杆菌

Figure 3. Bifidobacterium

下载: 全尺寸图片幻灯片

图 4 乳酸杆菌

Figure 4. Lactobacillus

下载: 全尺寸图片幻灯片

图 5 GAPDH

Figure 5. GAPDH

下载: 全尺寸图片幻灯片

图 6 溶解曲线图

A：多形拟杆菌；B：直肠真杆菌；C：双歧杆菌；D：乳酸杆菌；E：GAPDH。

Figure 6. Melted curve

下载: 全尺寸图片幻灯片

图 7 实时PCR扩增曲线图

A：多形拟杆菌；B：直肠真杆菌；C：双歧杆菌；D：乳酸杆菌；E：GAPDH。

Figure 7. The curve of real-time PCR

下载: 全尺寸图片幻灯片

表 1 NAFLD组与对照组目标细菌比较[M（P25，P75）]

Table 1. The target bacteria comparation of NAFLD and the control group[M（P25，P75）]

目标细菌	NAFLD组	正常对照组	Z	P
多形拟杆菌	1.99（0.671，6.311）	1.854，6.267	−2.23	0.022^*
直肠真杆菌	0.31（0.028，1.444）	0.003，0.340	−3.67	0.007^*
双歧杆菌	0.59（0.237，2.148）	1.053，10.602	−5.06	< 0.001^*
乳酸杆菌	0.24（0.001，0.247）	0.001，0.203	−2.68	< 0.001^*
^*P < 0.05。

下载: 导出CSV

参考文献(23)

[1]	Chalasani N,Younossi Z,Lavine J E,et al. The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2018,67(1):328-357. doi: 10.1002/hep.29367
[2]	Marshall J C. The gut as a potential trigger of exercise-induced inflammatory responses[J]. Can J Physiol Pharmacol,1998,76(5):479-484. doi: 10.1139/y98-049
[3]	Tilg H,Moschen A R. Evolution of inflammation in nonalcoholic fatty liver disease:the multiple parallel hits hypothesis[J]. Hepatology,2010,52(5):1836-1846. doi: 10.1002/hep.24001
[4]	Polyzos S A,Kountouras J,Mantzoros C S,et al. Obesity and nonalcoholic fatty liver disease:From pathophysiology to therapeutics[J]. Metabolism,2019,92(3):82-97.
[5]	Yufang Ding,Karin Yanagi,Clint Cheng,et al. Interactions between gut microbiota and non-alcoholic liver disease:The role of microbiota-derived metabolites[J]. Pharmacol Res,2019,141(5):521-529.
[6]	Jasirwan C O M,Lesmana C R A,Hasan I,et al. The role of gut microbiota in non-alcoholic fatty liver disease:pathways of mechanisms[J]. Biosci Microbiota Food Health,2019,38(3):81-88. doi: 10.12938/bmfh.18-032
[7]	Akhmedov V A,Gaus O V. Role of intestinal microbiota in the formation of non-alcoholic fatty liver disease[J]. Terapevticheskii Arkhiv,2019,91(2):143-148.
[8]	易艳容,曾亚,何佳,等. 非酒精性脂肪性肝病患者肠道菌群变化及双歧杆菌三联活菌胶囊对肠道菌群、肝功能、血脂及胰岛素抵抗的影响[J].中国肝脏病杂志(电子版),2016,8(3):87-92. doi: 10.3969/j.issn.1674-7380.2016.03.019
[9]	中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版)[J].中华肝脏病杂志,2010,18(3):163-166. doi: 10.3760/cma.j.issn.1007-3418.2010.03.002
[10]	Jayakumar S,Loomba R. Review article:emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications[J]. Aliment Pharmacol Ther,2019,50(2):144-158. doi: 10.1111/apt.15314
[11]	Alexander W,Lukas J G,Frank T. Microbiome & NASH-partners in crime driving progression of fatty liver disease[J]. Z Gastroenterol,2019,57(7):871-882. doi: 10.1055/a-0755-2595
[12]	Aleksandra A K,Danping Zheng,Oren S H,et al. The role of the microbiome in NAFLD and NASH[J]. EMBO Mol Med,2019,11(2):e9302.
[13]	Woodhouse C A,Patel V C,Singanayagam A,et al. Review article:the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease[J]. Aliment Pharmacol Ther,2018,47(2):192-202. doi: 10.1111/apt.14397
[14]	Lau L H S,Wong S H. Microbiota,obesity and NAFLD[J]. Adv Exp Med Biol,2018,1061(6):111-125.
[15]	Mouzaki M,Comelli E M,Arendt B M,et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease[J]. Hepatology,2013,58(1):120-127. doi: 10.1002/hep.26319
[16]	Wong V W,Tse C H,Lam T T,et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis-A longitudinal study[J]. PLoS One,2013,8(4):e62885. doi: 10.1371/journal.pone.0062885
[17]	Wang B,Jiang X,Cao M,et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease[J]. Sci Rep,2016,8(6):32002.
[18]	Da Silva H E,Teterina A,Comelli E M,et al. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance[J]. Sci Rep,2018,8(1):1466. doi: 10.1038/s41598-018-19753-9
[19]	Sobhonslidsuk A,Chanprasertyothin S,Pongrujikorn T,et al. The association of gut microbiota with nonalcoholic steatohepatitis in Thais[J]. Bio Med Res Int,2018,8(16):9340316.
[20]	Boursier J,Mueller O,Barret M,et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota[J]. Hepatology,2016,63(3):764-775. doi: 10.1002/hep.28356
[21]	Ge H,Li X,Weiszmann J,et al. Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids[J]. Endocrinology,2008,149(9):4519-4526. doi: 10.1210/en.2008-0059
[22]	Fetissov S O. Role of the gut microbiota in host appetite control:bacterial growth to animal feeding behaviour[J]. Nat Rev Endocrinol,2017,13(1):11-25. doi: 10.1038/nrendo.2016.150
[23]	Torres-Fuentes C,Schellekens H,Dinan T G,et al. The microbiota-gut-brain axis in obesity[J]. Lancet Gastroenterol Hepatol,2017,2(10):747-756. doi: 10.1016/S2468-1253(17)30147-4

相关文章(20)

[1]	李波, 孙杨, 缪应雷. 炎症性肠病的肠道微生态变化及对策, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240401
[2]	聂忠顺, 缪应雷. 生物制剂背景下粪菌移植对炎症性肠病的应用前景, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20241023
[3]	王艾云, 王雨婷, 蔡静, 倪若妍, 罗彩莹, 喻卓, 陈鹏. 肠道菌群及其代谢产物在动脉粥样硬化发生发展中的作用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20241223
[4]	牛俊杰, 姬文娟, 于拽拽. 肠道菌群、血清ET、PCT水平与脓毒症病情程度、预后的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240420
[5]	李媛媛, 宋亚贤, 徐玉善, 曾晓甫, 袁惠, 徐兆, 江艳. 肠道菌群代谢物TMAO与非酒精性脂肪性肝病的关系, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240210
[6]	李春, 周琼, 梅聪, 黄洁杰, 王毅鹏, 周松兰, 郑倩, 唐哲. 双歧杆菌三联活菌对小鼠非酒精性脂肪肝模型中肠道微生物组的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231022
[7]	徐琳, 高开成, 贾杰, 李煜阳, 王华伟, 况轶群, 赵昱. 参苓白术散对甲基苯丙胺诱导小鼠肠道菌群改变的作用机制研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230829
[8]	邓绍友, 赵玉兰, 王佩锦, 李蓉, 李进涛, 郑红. 恒古骨伤愈合剂联合广谱抗生素改善db/db小鼠胰岛素抵抗和肠道菌群, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230530
[9]	梁彩红, 孟明耀, 李欣欣, 熊晶晶, 李檬, 刘梅, 侯宗柳, 黄永坤. 肠道菌群代谢物脱氧胆酸对人脐带间充质干细胞hUC-MSCs增殖及细胞周期的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230402
[10]	李露, 田云粉. 肠道菌群与儿童非酒精性脂肪性肝病的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230708
[11]	李丹, 万绪莲, 李律宇, 云宇, 罗光云, 刘韦兵, 林公府, 李宁, 黎勇坤, 段为钢. 尿酸酶缺失大鼠肠道菌群的变化, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230205
[12]	杨顺航, 李炯明, 刘建和, 王光, 李沛. 肠源性高草酸尿症的发病机制与治疗进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220734
[13]	刘四香, 黄永坤, 王明英, 胡红卫, 马敏, 凌昱. 功能性便秘患儿的肠道菌群分析及治疗干预, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220309
[14]	唐娟, 念馨. 肠道微生态与肥胖相关性研究进展, 昆明医科大学学报.
[15]	戴海龙, 王南, 陈晓晴, 何臻一, 冯晓岚, 光雪峰. 冠心病患者肠道菌群的特征, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20201213
[16]	梁睿, 淳于纬训, 沈焘, 孙乐, 李云峰. 肠道菌群和免疫在结直肠肿瘤中作用研究进展, 昆明医科大学学报.
[17]	侯云鹤, 张皓鑫, 王依雨, 苏艳梅, 顾丹珊, 林少芳, 杨世昆, 李树德. 人参皂苷Rg1对NAFLD动物模型中同型半胱氨酸的调控机制, 昆明医科大学学报.
[18]	王瑞涛, 贾庆安, 牟怡平, 耿智敏, 刘昌. 胆宁片调节肠道菌群移位消除胆道炎症及预防胆石形成的临床评价, 昆明医科大学学报.
[19]	吴雪松, 孙锋, 鲍天昊, 柯阳, 王映华, 王华. Roux-en-Y胃旁路术对大鼠肠道厚壁菌群及APPL1的影响, 昆明医科大学学报.
[20]	杨静. 乙肝合并NAFLD患者肝功能及病毒复制与脂代谢水平相关性分析, 昆明医科大学学报.